DEVELOPMENT OF THE INJECTION PEN ASSESSMENT QUESTIONNAIRE (IPAQ) TO EVALUATE A NEW DEVICE TO ADMINISTER HUMAN GROWTH HORMONE (HGH)
Author(s)
Martine Etschmaier, MPH, Manager--Outcomes Research1, Miriam Kimel, PhD, Research Scientist2, Julie McCormack, MA, Senior Research Associate2, Judith Hey-Hadavi, DDS, MD, Medical Director1, José F Cara, MD, Senior Medical Director11Pfizer, New York, NY, USA; 2 United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES To develop a questionnaire that evaluates parent and child perception of attributes of injection devices (pens) used to administer hGH, particularly ease of use, convenience, and preference. METHODS Parent-child dyads with current experience using the Genotropin Pen® participated in focus groups (N=8 dyads) and cognitive debriefing interviews (N=8 dyads) to develop the IPAQ. Four focus groups identified attributes of injection devices relevant to children and/or parents of children being treated with hGH. The IPAQ was cognitively debriefed to assess the instrument's face validity, ease of administration, and item understandability. Focus group and debriefing transcripts were analyzed using ATLAS.ti. A translation assessment was performed and revisions were made to improve the usefulness of the IPAQ. RESULTS Ease of use and convenience regarding preparing the device, setting the dose, injecting the medicine, and maintaining the device were identified as major attributes influencing preference. Findings from the debriefings suggest that ease of use and convenience were considered similar concepts when evaluating device attributes. Equivalent terms describing the concept of convenience are difficult to find in languages other than English, where the term “convenient” is most often translated as “easy.” Revisions based on debriefings, translation assessment, and internal discussions resulted in a 29-item questionnaire: 14 items assessing ease of use for each device (5-point response scale ranging from “very easy” to “very difficult”), 14 items comparing ease of use for the two devices (“Genotropin Pen® easier to use,” “new injection pen easier to use,” and “no difference”), and 1 item assessing preference (“prefer Genotropin Pen®,” “prefer new injection pen,” and “no preference”). CONCLUSIONS The IPAQ, which assesses convenience/ease of use and preference for injection device attributes, can be used to evaluate and compare current and newly developed devices from the perspective of the parent-child dyad.
Conference/Value in Health Info
2009-05, ISPOR 2009, Orlando, FL, USA
Value in Health, Vol. 12, No. 3 (May 2009)
Code
PIH35
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Pediatrics